Developer docs
API playgroundTry for free, no card

Search company profiles

Santhera Pharmaceuticals

Full company profile

uuid0000cna

Namestring
Santhera Pharmaceuticals
Legal namestring
Santhera Pharmaceuticals (Schweiz) AG
Websiteurl
santhera.com
Company typeenum
Public
Founded yearint
2004
Descriptiontext

Santhera Pharmaceuticals is a Swiss specialty pharmaceutical company headquartered in Pratteln, Switzerland, founded in 2004 and listed on the SIX Swiss Exchange (ticker: SANN). The company develops and commercializes innovative medicines for rare neuromuscular and pulmonary diseases, with its primary commercial product being AGAMREE (vamorolone), a first-in-class dissociative steroid approved for Duchenne muscular dystrophy (DMD). Vamorolone binds to the same glucocorticoid and mineralocorticoid receptors as traditional corticosteroids but modifies downstream gene transcription, providing comparable anti-inflammatory efficacy with substantially reduced side effects, including an 80% reduction in vertebral fractures, a 12.17 cm mean height advantage at 5 years, and lower cataract incidence relative to standard-of-care corticosteroids. Santhera also has Lonodelestat (POL6014) in clinical development for cystic fibrosis.

The company operates a hybrid commercialization model combining direct field sales in major European markets (Germany, Austria, Italy, Spain, UK, Switzerland) with exclusive licensing partnerships in other regions: Catalyst Pharmaceuticals for North America (up to USD 231 million plus royalties), Sperogenix Therapeutics for Greater China, and Nxera Pharma for Japan, South Korea, Australia, and New Zealand (up to USD 205 million plus royalties). Distribution agreements extend further reach into Russia, Central and Eastern Europe, Turkey, India, and GCC countries. Revenue is generated through direct product sales of AGAMREE to wholesalers and pharmacies in directly commercialized markets, combined with upfront payments, milestone receipts, and tiered royalties from licensing partners. The company also employs royalty monetization structures (with R-Bridge and Partners Group) to extend its operational runway toward its targeted Q3 2026 cash flow breakeven, supported by FY2025 revenue of CHF 77.4 million representing 98% year-over-year growth.

Short descriptiontext

Santhera Pharmaceuticals is a Swiss specialty pharmaceutical company that develops and commercializes AGAMREE (vamorolone), a first-in-class dissociative steroid approved for Duchenne muscular dystrophy, serving patients across the US, EU, UK, China, and APAC markets through direct sales and licensing partnerships.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersPratteln, Switzerland
HQ citystring
Pratteln
HQ countrystring
Switzerland
HQ regionstring
Europe
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
rare disease therapeutics, neuromuscular disease drugs, dissociative steroid therapy, Duchenne muscular dystrophy treatment, specialty pharmaceuticals
Industry1 code
PRIMARYHLAIAIAK
Rare Ophthalmology Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Pharmaceutical and Medicine Manufacturing3254
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Specialty Pharmaceuticals - Rare Neuromuscular Disease Therapeutics
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model6 records
1AGAMREE Product Sales
TypeOne Time License
Description

Direct product sales of AGAMREE (vamorolone) for Duchenne muscular dystrophy in European markets where Santhera commercializes directly (Germany, Austria, Italy, Spain, UK), generating product revenue from pharmaceutical wholesalers and pharmacies.

biospace.com
2North America Licensing Royalties
TypeLicensing Royalties
Description

Out-licensed to Catalyst Pharmaceuticals for North America; Santhera receives royalties on net sales of AGAMREE in the US and Canada. Deal valued at up to USD 231 million plus royalties.

santhera.com
3China Licensing Royalties
TypeLicensing Royalties
Description

Out-licensed to Sperogenix Therapeutics for Greater China region; Santhera receives royalties on net sales of AGAMREE in China. Early access program launched in China in June 2024, with full approval from China's NMPA in December 2024.

santhera.com
4Japan/APAC Licensing
TypeLicensing Royalties
Description

Exclusive licensing agreement with Nxera Pharma for Japan, South Korea, Australia, and New Zealand. Deal includes USD 40 million upfront payment (USD 30M cash + USD 10M equity), plus potential milestone payments of up to USD 165 million and double-digit tiered royalties on net sales.

santhera.com
5Royalty Monetization
TypeLicensing Royalties
Description

Santhera monitized future royalty streams from Catalyst Pharmaceuticals (North America) and Sperogenix Therapeutics (China) for USD 13 million to support global AGAMREE launch.

uk.finance.yahoo.com
6Milestone Payments
TypeLicensing Royalties
Description

Received milestone payments from regulatory approvals and commercial launches across various territories, contributing to non-recurring revenue.

globenewswire.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels7 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations
Pricing details1 tier
1AGAMREE pricing determined through national reimbursement negotiations in each market
ModelOtherBilling cadenceOther
Notes

No public list pricing available. Drug is reimbursed through national health systems in EU (Germany, Italy, Spain, UK) and distributed via pharmacy channels. In North America, marketed by Catalyst Pharmaceuticals at US pricing. In China, distributed by Sperogenix Therapeutics.

santhera.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1AGAMREE (vamorolone)
Description

First-in-class dissociative steroid treatment for Duchenne muscular dystrophy

santhera.com
Core offering1 text field

Santhera Pharmaceuticals develops, manufactures, and commercializes AGAMREE (vamorolone), a first-in-class dissociative steroid approved for the treatment of Duchenne muscular dystrophy (DMD). The company also has a pipeline asset, Lonodelestat (POL6014), under development for cystic fibrosis. Santhera commercializes AGAMREE directly in major European markets and through exclusive licensing partners in North America, China, and Japan/APAC.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 80% reduction in vertebral fractures compared to standard corticosteroids (8.1% vs 41.9%)
+3 more records
Product overview1 text field

Santhera Pharmaceuticals is a Swiss specialty pharmaceutical company focused on development and commercialization of innovative medicines for rare diseases. The company's primary commercial product is AGAMREE (vamorolone), a first-in-class dissociative steroid approved for Duchenne muscular dystrophy (DMD) in the US, EU, UK, China, Hong Kong, Canada, and Switzerland. The product portfolio includes AGAMREE as the core commercial offering and Lonodelestat as a pipeline asset for cystic fibrosis. Santhera has out-licensed rights to vamorolone for North America to Catalyst Pharmaceuticals and for China to Sperogenix Therapeutics, while maintaining commercial rights in Europe and other regions. The company previously developed Raxone (idebenone) for Leber's Hereditary Optic Neuropathy and Puldysa for DMD but has divested these assets.

Product and service1 record
1AGAMREE (vamorolone)
CategoryDissociative steroid therapy for Duchenne muscular dystrophy
Description

AGAMREE is a first-in-class dissociative steroid (vamorolone) approved for the treatment of Duchenne muscular dystrophy (DMD) in patients typically aged 4 years and older (expanding to 2+ years in EU following CHMP positive opinion). It binds to glucocorticoid and mineralocorticoid receptors but modifies downstream gene transcription, delivering anti-inflammatory efficacy comparable to standard corticosteroids with significantly reduced side effects (80% reduction in vertebral fractures, 12.17 cm height advantage at 5 years, fewer cataracts). It is for neuromuscular specialists, pediatricians, hospital pharmacies, and national health systems that reimburse orphan disease treatments.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

US-based specialty pharmaceutical company developing and commercializing treatments for Duchenne muscular dystrophy and other rare disorders. Directly comparable as a DMD-focused rare-disease commercial-stage peer with overlapping physician call points and similar orphan-drug commercial dynamics.

TypeDirect peer
Description

Leading commercial-stage DMD therapeutics company (Elevidys, EXONDYS 51, etc.). Competes for the same DMD patient population and neuromuscular specialists, with overlapping distribution and reimbursement infrastructure in the US and EU.

TypeDirect peer
Description

Santhera's exclusive North America licensee for AGAMREE and a US rare-disease commercial specialist (Firdapse, etc.). Closely linked commercially and a directly comparable rare-disease specialty pharma business model.

TypeDirect peer
Description

Privately held Italian pharmaceutical company marketing deflazacort (the standard-of-care corticosteroid against which vamorolone competes) in DMD across multiple geographies. Direct therapeutic competitor in the same indication.

TypeEmerging player
Description

Originating discoverer of vamorolone and licensor of the compound to Santhera. A clinical-stage rare-disease biotech whose commercial economics flow through Santhera but whose scientific footprint defines the platform.

TypeBroad incumbent
Description

Swiss specialty pharmaceutical company and a significant Santhera shareholder (~17.7%). Comparable as a Switzerland-listed, late-stage commercial rare-disease and CNS-focused peer with similar operating profile and geographic base.

TypeBroad incumbent
Description

Swiss specialty pharma with established global rare-disease and nephrology commercial infrastructure. Many Santhera executives (Eklund, Kronenberg) came from Vifor, making it a relevant operational and strategic peer.

TypeBroad incumbent
Description

Established global rare-disease specialty pharmaceutical company with a multi-asset commercial portfolio. Comparable as a larger, more diversified rare-disease commercial peer operating similar specialty distribution and reimbursement models.

TypeBroad incumbent
Description

European-headquartered specialty pharmaceutical group with a growing rare-disease franchise. Comparable as a European specialty pharma commercializing rare-disease treatments through similar national reimbursement pathways.

TypeEmerging player
Description

US rare-disease specialty pharma with growing international operations (where incoming Santhera CCO Marc Clausse previously worked). Comparable as a smaller, focused rare-disease commercial peer building global rare-disease infrastructure.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

Integration1 record

Each record includes

Title, Type, Description, Source

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles14 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries3 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds14 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors18 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Santhera Pharmaceuticals

Specialty Pharmaceuticals - Rare Neuromuscular Disease Therapeuticssanthera.com

Santhera Pharmaceuticals is a Swiss specialty pharmaceutical company that develops and commercializes AGAMREE (vamorolone), a first-in-class dissociative steroid approved for Duchenne muscular dystrophy, serving patients across the US, EU, UK, China, and APAC markets through direct sales and licensing partnerships.

What Santhera Pharmaceuticals does

Santhera Pharmaceuticals is a Swiss specialty pharmaceutical company headquartered in Pratteln, Switzerland, founded in 2004 and listed on the SIX Swiss Exchange (ticker: SANN). The company develops and commercializes innovative medicines for rare neuromuscular and pulmonary diseases, with its primary commercial product being AGAMREE (vamorolone), a first-in-class dissociative steroid approved for Duchenne muscular dystrophy (DMD). Vamorolone binds to the same glucocorticoid and mineralocorticoid receptors as traditional corticosteroids but modifies downstream gene transcription, providing comparable anti-inflammatory efficacy with substantially reduced side effects, including an 80% reduction in vertebral fractures, a 12.17 cm mean height advantage at 5 years, and lower cataract incidence relative to standard-of-care corticosteroids. Santhera also has Lonodelestat (POL6014) in clinical development for cystic fibrosis.

The company operates a hybrid commercialization model combining direct field sales in major European markets (Germany, Austria, Italy, Spain, UK, Switzerland) with exclusive licensing partnerships in other regions: Catalyst Pharmaceuticals for North America (up to USD 231 million plus royalties), Sperogenix Therapeutics for Greater China, and Nxera Pharma for Japan, South Korea, Australia, and New Zealand (up to USD 205 million plus royalties). Distribution agreements extend further reach into Russia, Central and Eastern Europe, Turkey, India, and GCC countries. Revenue is generated through direct product sales of AGAMREE to wholesalers and pharmacies in directly commercialized markets, combined with upfront payments, milestone receipts, and tiered royalties from licensing partners. The company also employs royalty monetization structures (with R-Bridge and Partners Group) to extend its operational runway toward its targeted Q3 2026 cash flow breakeven, supported by FY2025 revenue of CHF 77.4 million representing 98% year-over-year growth.

Santhera Pharmaceuticals firmographics

Firmographics
Name
Santhera Pharmaceuticals
Legal name
Santhera Pharmaceuticals (Schweiz) AG
Website
https://santhera.com
Company type
Public
Founded year
2004
Operating status
Operating
Headcount range
101–250 employees
Short description
Santhera Pharmaceuticals is a Swiss specialty pharmaceutical company that develops and commercializes AGAMREE (vamorolone), a first-in-class dissociative steroid approved for Duchenne muscular dystrophy, serving patients across the US, EU, UK, China, and APAC markets through direct sales and licensing partnerships.
Ownership category
akta.pro rank

Santhera Pharmaceuticals industry classification

Industry
Product category
Specialty Pharmaceuticals - Rare Neuromuscular Disease Therapeutics
NAICS
Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAIAK
Rare Ophthalmology Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals

Keywords

  • Rare disease therapeutics
  • Neuromuscular disease drugs
  • Dissociative steroid therapy
  • Duchenne muscular dystrophy treatment
  • Specialty pharmaceuticals

Where Santhera Pharmaceuticals is headquartered

Location

Headquarters

HQ city
Pratteln
HQ country
Switzerland
HQ region
Europe

Offices4 records

Markets served

Santhera Pharmaceuticals business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations

Revenue model

  1. AGAMREE Product Sales: Direct product sales of AGAMREE (vamorolone) for Duchenne muscular dystrophy in European markets where Santhera commercializes directly (Germany, Austria, Italy, Spain, UK), generating product revenue from pharmaceutical wholesalers and pharmacies.
  2. North America Licensing Royalties: Out-licensed to Catalyst Pharmaceuticals for North America; Santhera receives royalties on net sales of AGAMREE in the US and Canada. Deal valued at up to USD 231 million plus royalties.
  3. China Licensing Royalties: Out-licensed to Sperogenix Therapeutics for Greater China region; Santhera receives royalties on net sales of AGAMREE in China. Early access program launched in China in June 2024, with full approval from China's NMPA in December 2024.
  4. Japan/APAC Licensing: Exclusive licensing agreement with Nxera Pharma for Japan, South Korea, Australia, and New Zealand. Deal includes USD 40 million upfront payment (USD 30M cash + USD 10M equity), plus potential milestone payments of up to USD 165 million and double-digit tiered royalties on net sales.
  5. Royalty Monetization: Santhera monitized future royalty streams from Catalyst Pharmaceuticals (North America) and Sperogenix Therapeutics (China) for USD 13 million to support global AGAMREE launch.
  6. Milestone Payments: Received milestone payments from regulatory approvals and commercial launches across various territories, contributing to non-recurring revenue.

Pricing tiers

ModelBillingPrice
OtherOtherAGAMREE pricing determined through national reimbursement negotiations in each market

Go-to-market motion1 record

Distribution channels7 records

Marketing channels6 records

Santhera Pharmaceuticals product offering

Product offering

Core offering

Santhera Pharmaceuticals develops, manufactures, and commercializes AGAMREE (vamorolone), a first-in-class dissociative steroid approved for the treatment of Duchenne muscular dystrophy (DMD). The company also has a pipeline asset, Lonodelestat (POL6014), under development for cystic fibrosis. Santhera commercializes AGAMREE directly in major European markets and through exclusive licensing partners in North America, China, and Japan/APAC.

Product overview

Santhera Pharmaceuticals is a Swiss specialty pharmaceutical company focused on development and commercialization of innovative medicines for rare diseases. The company's primary commercial product is AGAMREE (vamorolone), a first-in-class dissociative steroid approved for Duchenne muscular dystrophy (DMD) in the US, EU, UK, China, Hong Kong, Canada, and Switzerland. The product portfolio includes AGAMREE as the core commercial offering and Lonodelestat as a pipeline asset for cystic fibrosis. Santhera has out-licensed rights to vamorolone for North America to Catalyst Pharmaceuticals and for China to Sperogenix Therapeutics, while maintaining commercial rights in Europe and other regions. The company previously developed Raxone (idebenone) for Leber's Hereditary Optic Neuropathy and Puldysa for DMD but has divested these assets.

Differentiator

Problem solved

Functional benefit

Brands

  • AGAMREE (vamorolone): First-in-class dissociative steroid treatment for Duchenne muscular dystrophy

Products and services

  • AGAMREE (vamorolone) AGAMREE is a first-in-class dissociative steroid (vamorolone) approved for the treatment of Duchenne muscular dystrophy (DMD) in patients typically aged 4 years and older (expanding to 2+ years in EU following CHMP positive opinion). It binds to glucocorticoid and mineralocorticoid receptors but modifies downstream gene transcription, delivering anti-inflammatory efficacy comparable to standard corticosteroids with significantly reduced side effects (80% reduction in vertebral fractures, 12.17 cm height advantage at 5 years, fewer cataracts). It is for neuromuscular specialists, pediatricians, hospital pharmacies, and national health systems that reimburse orphan disease treatments.

Quantifiable outcome

  • 80% reduction in vertebral fractures compared to standard corticosteroids (8.1% vs 41.9%)
  • +3 more outcomes

Companies that use Santhera Pharmaceuticals

Customer profile

Named customers3 records

Segments1 record

Ideal customer profiles1 record

Santhera Pharmaceuticals technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration1 record

Feature1 record

Santhera Pharmaceuticals partnerships and signals

Strategic signal

Scale indicators9 records

Recent moves8 records

Expansion highlights6 records

Santhera Pharmaceuticals competitors and assessment

Company assessment

Direct peers

  • PTC Therapeutics: US-based specialty pharmaceutical company developing and commercializing treatments for Duchenne muscular dystrophy and other rare disorders. Directly comparable as a DMD-focused rare-disease commercial-stage peer with overlapping physician call points and similar orphan-drug commercial dynamics.
  • Sarepta Therapeutics: Leading commercial-stage DMD therapeutics company (Elevidys, EXONDYS 51, etc.). Competes for the same DMD patient population and neuromuscular specialists, with overlapping distribution and reimbursement infrastructure in the US and EU.
  • Catalyst Pharmaceuticals: Santhera's exclusive North America licensee for AGAMREE and a US rare-disease commercial specialist (Firdapse, etc.). Closely linked commercially and a directly comparable rare-disease specialty pharma business model.
  • Italfarmaco: Privately held Italian pharmaceutical company marketing deflazacort (the standard-of-care corticosteroid against which vamorolone competes) in DMD across multiple geographies. Direct therapeutic competitor in the same indication.

Emerging players

  • ReveraGen BioPharma: Originating discoverer of vamorolone and licensor of the compound to Santhera. A clinical-stage rare-disease biotech whose commercial economics flow through Santhera but whose scientific footprint defines the platform.
  • Mirum Pharmaceuticals: US rare-disease specialty pharma with growing international operations (where incoming Santhera CCO Marc Clausse previously worked). Comparable as a smaller, focused rare-disease commercial peer building global rare-disease infrastructure.

Broad incumbents

  • Idorsia Pharmaceuticals: Swiss specialty pharmaceutical company and a significant Santhera shareholder (~17.7%). Comparable as a Switzerland-listed, late-stage commercial rare-disease and CNS-focused peer with similar operating profile and geographic base.
  • Vifor Pharma: Swiss specialty pharma with established global rare-disease and nephrology commercial infrastructure. Many Santhera executives (Eklund, Kronenberg) came from Vifor, making it a relevant operational and strategic peer.
  • BioMarin Pharmaceutical: Established global rare-disease specialty pharmaceutical company with a multi-asset commercial portfolio. Comparable as a larger, more diversified rare-disease commercial peer operating similar specialty distribution and reimbursement models.
  • Recordati: European-headquartered specialty pharmaceutical group with a growing rare-disease franchise. Comparable as a European specialty pharma commercializing rare-disease treatments through similar national reimbursement pathways.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

Santhera Pharmaceuticals social profiles

Digital presence

Santhera Pharmaceuticals financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Santhera Pharmaceuticals leadership team

Management profile

Number of profiles

Profiles14 records

Santhera Pharmaceuticals subsidiaries and ownership

Company hierarchy

Subsidiaries3 records

Santhera Pharmaceuticals funding detail

Funding detail

Funding overview

Funding rounds14 records

Investors18 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Santhera Pharmaceuticals M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Santhera Pharmaceuticals

What does Santhera Pharmaceuticals do?

Santhera Pharmaceuticals develops, manufactures, and commercializes AGAMREE (vamorolone), a first-in-class dissociative steroid approved for the treatment of Duchenne muscular dystrophy (DMD). The company also has a pipeline asset, Lonodelestat (POL6014), under development for cystic fibrosis. Santhera commercializes AGAMREE directly in major European markets and through exclusive licensing partners in North America, China, and Japan/APAC.

Is Santhera Pharmaceuticals a public or private company?

Santhera Pharmaceuticals is a public company. It is classified as public and is currently operating.

When was Santhera Pharmaceuticals founded?

Santhera Pharmaceuticals was founded in 2004. It employs 101 to 250 people.

Where is Santhera Pharmaceuticals based?

Santhera Pharmaceuticals is headquartered in Pratteln, Switzerland, in the Europe region.

How does Santhera Pharmaceuticals make money?

Six revenue lines are on record. AGAMREE Product Sales are the primary driver. The others are north America Licensing Royalties, china Licensing Royalties, japan/APAC Licensing, royalty Monetization and milestone Payments.

Who are Santhera Pharmaceuticals's main competitors?

Direct peers on record are PTC Therapeutics, Sarepta Therapeutics, Catalyst Pharmaceuticals and Italfarmaco. Emerging players are ReveraGen BioPharma and Mirum Pharmaceuticals. Broad incumbents are Idorsia Pharmaceuticals, Vifor Pharma, BioMarin Pharmaceutical and Recordati.

Does Santhera Pharmaceuticals have an API?

No public API is recorded for Santhera Pharmaceuticals.

What industry is Santhera Pharmaceuticals in?

Santhera Pharmaceuticals's product category is Specialty Pharmaceuticals - Rare Neuromuscular Disease Therapeutics. Its primary akta.pro industry code is HLAIAIAK, Rare Ophthalmology Disorder Therapies. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
In VivoJefferies 2026: Santhera On The Hunt For Assets To Add To AgamreeSanthera Pharmaceuticals is seeking late-stage product deals to add to its portfolio, according to CEO Orlando Oliveira. The Swiss group cites its successful commercial launches of Agamree for Duchenne muscular dystrophy as establishing it as a credible partner in the rare disease space.Business & FinancialSanthera Signs Distribution Agreement With Steincares For AGAMREE® (Vamorolone) In 31 Countries Across Latin America And The CaribbeanSanthera signed a distribution agreement with SteinCares to bring AGAMREE (vamorolone) to 31 Latin American and Caribbean countries, including Brazil, Colombia, and Argentina. The launch will initially focus on Brazil, where SteinCares will pursue regulatory registration and access through exceptional importation pathways. Santhera will receive a percentage of net sales.FinanzNachrichten.deSanthera Pharmaceuticals Holding AG: Santheras Lizenzpartner Nxera Pharma reicht in Südkorea einen Antrag auf Marktzulassung für AGAMREE (Vamorolon) einNxera Pharma submitted a marketing authorization application for AGAMREE (Vamorolon) for Duchenne muscular dystrophy to South Korea's MFDS. The application follows an orphan drug designation and fast-track status, with Nxera targeting approval in 2027 and market launch in 2028.YahooSanthera Pharmaceuticals Holding AG (SPHDF) (H1 2026) Earnings Call Highlights: Revenue Doubles ...Santhera Pharmaceuticals reported H1 2026 revenue of CHF48.3 million, up over 100% year-over-year, driven by AGAMREE sales and Nxera licensing. Product sales grew 48% and operating loss narrowed to CHF6.6 million. The company guided full-year 2026 revenue to CHF80-90 million and 2030 revenue to EUR250 million.Seeking AlphaSanthera Pharmaceuticals Holding AG (SPHDF) Q2 2026 Earnings Call TranscriptSanthera Pharmaceuticals reported Q2 2026 results with four of five major EU markets commercially launched, including Spain and Italy. Germany volumes rose 50% year-over-year, and the U.K. grew 40% in Q2. The company also signed a strategic APAC licensing agreement with Nxera focused on Japan and South.FinanzNachrichten.deSanthera steigert Umsatz im H1 markant und verringert VerlustSanthera reported a significant increase in first-half revenue and a reduced loss. Revenue rose to 48.3 million Swiss francs, more than double the prior period, driven by its product Agamree for Duchenne muscular dystrophy.FinanzNachrichten.deSanthera Pharmaceuticals Holding AG: Santhera Pharmaceuticals Halbjahresergebnisse für die sechs Monate bis zum 30. Juni 2026Santhera Pharmaceuticals reported H1 2026 revenue of 48.3 million CHF, up 101% year-over-year, driven by AGAMREE sales and Nxera licensing fees. The company expanded AGAMREE availability to four of five major EU markets and signed a $215 million APAC licensing deal with Nxera. It also presented long-term efficacy data for DMD patients.FinancialContent Business PageSanthera Pharmaceuticals Half Year Results for the six months ending 30 June 2026Santhera Pharmaceuticals reported H1 2026 revenue of CHF 48.3 million, up 101% year-over-year, driven by product sales and the Nxera licensing agreement. AGAMREE® is now commercially available in four of five major EU markets, and the company guided full-year revenue to CHF 80–90 million.TradingViewSanthera Pharmaceuticals Half Year Results for the six months ending 30 June 2026Santhera Pharmaceuticals reported H1 2026 revenue of CHF 48.3 million, up 101% year-over-year, with product sales of CHF 17.2 million and royalties and milestones of CHF 29.1 million. AGAMREE® is now commercially available in four of five major EU markets, and the company maintains its full-year revenue guidance of CHF 80–90 million.TradingViewSanthera Pharmaceuticals Holding AG (S3F0) H1 Revenue CHF 48.3M; Net Loss NarrowsSanthera Pharmaceuticals reported H1 2026 revenue of CHF 48.3M, up from CHF 24.0M, and a net loss of CHF -21.5M, down from CHF -38.8M. The company reiterated 2026 revenue guidance of CHF 80–90M and opex of CHF 50–55M, citing improved cash flow and product sales.